LIFECORE BIOMEDICAL, INC. Proceeds from Long-term Lines of Credit
LIFECORE BIOMEDICAL, INC. (LFCR) reported Proceeds from Long-term Lines of Credit of $64.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. proceeds from long-term lines of credit for the quarter ending 2026-06-30 was $28.00M.
- LIFECORE BIOMEDICAL, INC. proceeds from long-term lines of credit for the quarter ending 2026-03-31 was $36.40M.
- LIFECORE BIOMEDICAL, INC. proceeds from long-term lines of credit for the quarter ending 2025-09-30 was $12.10M.
- LIFECORE BIOMEDICAL, INC. proceeds from long-term lines of credit for the quarter ending 2025-05-25 was $32.60M.
- LIFECORE BIOMEDICAL, INC. proceeds from long-term lines of credit for fiscal 2025 was $128.57M, a 14.05% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. proceeds from long-term lines of credit for fiscal 2024 was $149.59M.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 7 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $64.40M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $36.40M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $61.13M 10-KT · filed 2026-03-16 | |||
| 2025-09-30 | $12.10M 10-Q · filed 2025-11-06 | |||
| 2025-05-25 | $32.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $60.49M 10-Q · filed 2026-08-05 | $128.57M 10-KT · filed 2026-03-16 | |
| 2025-02-23 | $27.89M 10-Q · filed 2026-05-06 | |||
| 2024-08-25 | $31.82M 10-Q · filed 2025-11-06 | |||
| 2024-05-26 | $149.59M 10-KT · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |